Skip to main content
. 2016 Aug 5;7(40):66182–66191. doi: 10.18632/oncotarget.11097

Figure 2. Forest plots of overall incidences of all-grade and high-grade hemorrhagic events in cancer patients treated with ramucirumab.

Figure 2

A., overall incidence of all-grade hemorrhagic events; B., overall incidence of high-grade hemorrhagic events.